en Anglais
af Afrikaanssq Albanaisam Amharicar Arabehy Arménienaz Azerbaïdjanaiseu Basquebe Biélorussebn Bengalibs Bosnienbg Bulgareca Catalanceb Cebuanony Chichewazh-CN Chinois (simplifié)zh-TW Chinois (traditionnel)co Corsehr Croatecs Tchèqueda Danoisnl Néerlandaisen Anglaiseo Esperantoet Estonientl Philippinfi En finnoisfr Françaisfy Frisongl Galicienka Géorgiende Allemandel Grecgu Gujaratiht Créole haïtienha Hausahaw Hawaïenneiw En hébreuhi Hindihmn Hmonghu Hongroisis Islandaisig Igboid Indonésienga Irlandaisit Italienja Japonaisjw Javanaiskn Kannadakk Kazakhkm Khmerko Coréenku Kurde (Kurmanji)ky Kirghizelo Laola Latinlv Lettonlt En lituanienlb En luxembourgeoismk Macédonienmg Malgachems Malaisml Malayalammt Maltaismi Maorimr Marathimn Mongolmy Myanmar (Birmanie)ne Népalaisno Norvégienps Pachtounefa Persanpl Polonaispt Portugaispa Punjabiro En roumainru Russesm Samoangd Gaélique écossaissr Serbest Sesothosn Shonasd Sindhisi Sinhalask Slovaquesl Slovèneso Somalienes Espagnolsu Soudanaissw Swahilisv Suédoistg Tadjikta Tamilte Teluguth Thaitr Turcuk Ukrainienur Urduuz Ouzbékistanvi Vietnamiency Galloisxh Xhosayi Yiddishyo Yorubazu Zulu

Blog des aidants

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR!! May this year increase your hope and happiness! Let’s go forward together to Defeat MSA forever! We thank you for your continued support! www.msacanada.ca/donate-to-us/ #defeatmsa #kickmsa

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MSA BLOGUE 

Blog de l'avocat

REGISTER NOW – MSA VIRTUAL FREE CONFERENCE, SEPT 24-OCT 2

REGISTER NOW – MSA VIRTUAL FREE CONFERENCE, SEPT 24-OCT 2

Defeat MSA Canada/Vaincre AMS Canada, Defeat MSA Alliance (US) and allied charities in the MSA United Consortium are pleased to announce the Second All-Community MSA Virtual Conference, Sept 24-Oct 2, 2021. This year's conference will include several exciting...

GET SOME GEAR & RAISE AWARENESS ALL YEAR LONG!

GET SOME GEAR & RAISE AWARENESS ALL YEAR LONG!

Defeat MSA Canada/Vaincre L’AMS Canada Board Member & MSA Patient Advocate Kelly Murphy tests out the new mug! Maybe a 'wee nip of something strong?  Order One Now! www.MSAcanada.ca There are also online stores for some of our affiliated MSA United charites:...

Blog des chercheurs

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MODAG Collaboration Update – MSA Drug

MODAG Collaboration Update – MSA Drug

Congratulations to MODAG! On behalf of MSA/AMS patients around the world, we are thankful for your efforts! 💜. https://www.tevapharm.com/news-and-media/latest-news/teva-and-modag-announce-licensing-collaboration-for-neurodegenerative-disease-drug-candidate/

Patient’s Blog

You May Also Like…

Français du Canada